Omee D Capsule

These systemic azole antifungals are potent inhibitors of the CYP3A4 enzyme system. Studies confirm that drugs like ketoconazole cause a marked inhibition of Omee D Capsule's metabolism, leading to a three-fold increase in blood exposure and resulting in significant QTc interval prolongation. Additionally, Omee D Capsule decreases stomach acidity, which severely reduces the absorption and clinical efficacy of ketoconazole and itraconazole.

These antibiotics are known to prolong the QTc interval on an electrocardiogram. When taken alongside Omee D Capsule, they create a hazardous additive effect that increases the risk of severe ventricular arrhythmias.

Omee D Capsule acts as a moderate CYP2C19 inhibitor and interacts with clopidogrel to decrease the conversion to its active metabolite by an average of 46%. This interaction also reduces the maximum inhibition of platelet aggregation by an average of 16%, potentially making clopidogrel less effective at preventing blood clots.

These calcium channel blockers act as moderate CYP3A4 inhibitors. Because Omee D Capsule is primarily processed through the CYP3A4 enzyme, taking these medications concurrently can result in increased plasma levels of the capsule and elevate your risk of heart rhythm disorders.

These specific anti-psychotic medications can interact to heavily increase plasma levels of the domperidone component in Omee D Capsule and compound the risk of serious cardiac side effects, including QT-interval prolongation and torsades de pointes.

These Class III anti-arrhythmic drugs cause a dangerous pharmacodynamic and pharmacokinetic interaction when taken with Omee D Capsule, heavily increasing your vulnerability to QT-interval prolongation, ventricular arrhythmias, and sudden cardiac death.

Combining these Class IA anti-arrhythmic medications with Omee D Capsule significantly increases the risk of serious cardiac conduction abnormalities, specifically QT-interval prolongation, which can trigger life-threatening irregular heart rhythms.

These HIV protease inhibitors act as potent CYP3A4 inhibitors. Regardless of their individual effects on the QT interval, they significantly block the main metabolic pathway of Omee D Capsule, causing it to build up to dangerous levels in your body and increasing the risk of serious side effects.

Apomorphine is a QT-prolonging drug. Combining it with Omee D Capsule increases the risk of severe ventricular arrhythmias unless specific precautions are taken and the therapeutic benefit clearly outweighs the potential risks.

These specific antihistamines can cause QT-interval prolongation. When combined with Omee D Capsule, they significantly increase the likelihood of developing dangerous heart rhythms due to additive cardiac risks.

Omee D Capsule significantly reduces the absorption and plasma levels of atazanavir by lowering gastric acidity. Combining the medications results in up to a 75% decrease in atazanavir exposure, which can completely impair the efficacy of your antiviral treatment.

Nelfinavir is an antiretroviral medication whose plasma levels are drastically reduced when taken with Omee D Capsule due to decreased stomach acidity. Omee D Capsule lowers nelfinavir exposure by roughly 40% and reduces its active metabolite by 75-90%, which can cause your HIV treatment to fail. Additionally, nelfinavir acts as a protease inhibitor, which can unsafely raise the capsule's blood levels.

These gastrointestinal medicines are known to prolong the cardiac QT interval. Taking them together with Omee D Capsule multiplies the proarrhythmic risk, making serious cardiac conduction issues much more likely to occur.

The decreased stomach acidity caused by Omee D Capsule significantly reduces the absorption of posaconazole and erlotinib, which can severely impair their clinical efficacy and cause your treatment to fail.

Omee D Capsule increases the bioavailability and absorption of digoxin by 10% due to changes in stomach pH. Additionally, prolonged use of proton pump inhibitors can cause low magnesium levels (hypomagnesaemia), which heavily increases the risk of serious digoxin toxicity.

These specific macrolide antibiotics are involved in QT-interval prolongation. While they are not potent enzyme inhibitors like clarithromycin, combining them with Omee D Capsule still requires extreme care to prevent cumulative proarrhythmic risks.